Ensol Biosciences Statistics
Total Valuation
Ensol Biosciences has a market cap or net worth of KRW 53.60 billion.
Market Cap | 53.60B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Ensol Biosciences has 8.62 million shares outstanding.
Shares Outstanding | 8.62M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 24.28% |
Owned by Institutions (%) | 5.36% |
Float | 5.16M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 97.11 |
PB Ratio | 7.95 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.46.
Current Ratio | 9.01 |
Quick Ratio | 8.46 |
Debt / Equity | 0.46 |
Debt / EBITDA | n/a |
Debt / FCF | -0.01 |
Interest Coverage | -2,544.54 |
Financial Efficiency
Return on equity (ROE) is -59.14% and return on invested capital (ROIC) is -35.28%.
Return on Equity (ROE) | -59.14% |
Return on Assets (ROA) | -31.45% |
Return on Capital (ROIC) | -35.28% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.17% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -48.17% |
50-Day Moving Average | 6,090.60 |
200-Day Moving Average | 5,519.25 |
Relative Strength Index (RSI) | 52.40 |
Average Volume (20 Days) | 12,681 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ensol Biosciences had revenue of KRW 537.46 million and -5.40 billion in losses. Loss per share was -644.00.
Revenue | 537.46M |
Gross Profit | 153.05M |
Operating Income | -5.17B |
Pretax Income | -5.40B |
Net Income | -5.40B |
EBITDA | -4.77B |
EBIT | -5.17B |
Loss Per Share | -644.00 |
Balance Sheet
The company has 2.62 billion in cash and 30.00 million in debt, giving a net cash position of 2.59 billion or 300.81 per share.
Cash & Cash Equivalents | 2.62B |
Total Debt | 30.00M |
Net Cash | 2.59B |
Net Cash Per Share | 300.81 |
Equity (Book Value) | 6.56B |
Book Value Per Share | 782.26 |
Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was -4.65 billion and capital expenditures -142.78 million, giving a free cash flow of -4.80 billion.
Operating Cash Flow | -4.65B |
Capital Expenditures | -142.78M |
Free Cash Flow | -4.80B |
FCF Per Share | -556.54 |
Margins
Gross Margin | 28.48% |
Operating Margin | -961.08% |
Pretax Margin | -1,005.43% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -892.34% |
Dividends & Yields
Ensol Biosciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -10.35% |
FCF Yield | -8.95% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |